Default Category
-
Tale of Two Electronic Components Distributors (Spanish Version)
Raman, Ananth; Rao, Bharat P.Case HBS-604S15Service and Operations ManagementDiscute el papel de los intermediarios de distribución en la industria de componentes electrónicos, y describe las operaciones en dos de estos distribuidores. Sirve como un vehículo para discutir las funciones proporcionadas por los distribuidores en el canal. También permite a los estudiantes a entender las diferencias entre los distribuidores y discutir cómo cada uno de ellos va a hacer frente a cuestiones como la consolidación y el rápido crec...Starting at €8.20
-
Improving the Patient Experience (Spanish version)
Raman, Ananth; Tucker, AnitaCase HBS-615S02Service and Operations ManagementHealthcare has traditionally focused on medical outcomes and financial performance. The big question is always, "How much is it going to cost?" What would happen, though, if healthcare also considered the question of "How does the patient feel?" This case looks at the Cleveland Clinic's attempt to answer the latter question by attempting to institutionalize empathy as part of its delivery of care.Starting at €8.20
-
Merck: Investing in Science-Based Business (Abridged)
Raman, Ananth; Maurer, IngaCase HBS-611027-EService and Operations ManagementRay Gilmartin faces a dilemma. His company's credibility has been damaged by the recent withdrawal of Vioxx, a multi-billion dollar drug. Moreover, the withdrawal of Vioxx would imply that Merck would fail to meet analysts' earnings expectations for 2005 unless Gilmartin cuts the R&D budget. Cutting the budget might hurt morale and productivity in Merck labs.Starting at €8.20
-
Cleveland Clinic: Improving the Patient Experience
Raman, Ananth; Tucker, AnitaCase HBS-612031-EService and Operations ManagementHealthcare has traditionally focused on medical outcomes and financial performance. The big question is always, "How much is it going to cost?" What would happen, though, if healthcare also considered the question of "How does the patient feel?" This case looks at the Cleveland Clinic's attempt to answer the latter question by attempting to institutionalize empathy as part of its delivery of care.Starting at €8.20
-
Merck: Operating Science-Based Business
Raman, Ananth; Maurer, Inga; Schmidt, WilliamCase HBS-612082-EService and Operations ManagementMerck is known for its commitment to investing in basic R&D. Are Merck's long-term investments justifiable when the firm faces extreme earnings pressure?Starting at €8.20
-
Amgen Inc.: Pursuing Innovation and Imitation? (A)
Mackenzie, Ian WCase HBS-714424-EStrategySet in 2009, the (A) case explores whether Amgen, a leading innovator of biotech-based drugs, should enter the emerging business of biosimilars (BS), which are essentially 'me-too' products. There appear to be sound reasons to explore this related diversification: innovation is getting harder, regulators are intent on encouraging BS, and Amgen needs renewed growth. But the possibility sparked a strong negative reaction within Amgen, not least bec...Starting at €8.20
-
Uber and the Taxi Industry (A)
Casadesus-Masanell, Ramon; Mackenzie, Ian W; Dadiomov, DimitriCase HBS-715433-EStrategyStarting at €8.20
-
UberX & Lyft (B)
Casadesus-Masanell, Ramon; Mackenzie, Ian W; Dadiomov, DimitriCase HBS-715434-EStrategySupplement case for 715433.Starting at €5.74
-
Pursuing Innovation and Imitation? (A) (Spanish version)
Mackenzie, Ian WCase HBS-719S12Strategyinnovation is getting harder, regulators are intent on encouraging BS, and Amgen needs renewed growth. But the possibility sparked a strong negative reaction within Amgen, not least because it contravened Amgen's mission. Internal debate was exacerbated by the presence of considerable uncertainty over the regulatory requirements for BS development and how difficult it would be to develop a BS. Some felt it played to Amgen's strengths, others fel...Starting at €8.20
-
Amgen Inc.: Pursuing Innovation and Imitation (B)
Mackenzie, Ian WCase HBS-714426-EStrategyThe (B) case reveals that Sharer decided that Amgen should the emerging biosimilars business. However, he took the better part of a year to syndicate the decision across the senior team while in parallel investing in some time-critical process development. The (B) case then focuses on how the new business should be implemented, particularly in terms of integration versus separation of a new business unit, choice of unit leader, and whether Amgen ...Starting at €5.74